European Commission grants marketing authorization for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral adrenoleukodystrophy (cALD), a rare neurodegenerative disease

Дата публикации: 26-09-2026 04:16:00

Neuraxpharm Group and Minoryx Therapeutics, today announce that the European Commission (EC) has granted marketing authorization under exceptional circumstances for NEZGLYAL® (leriglitazone), an orally bioavailable, brain penetrating, selective PPAR gamma agonist, as a treatment for male cALD patients, aged 2-12 years with Gadolinium (Gd)-negative brain lesions.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Lynavoy (linerixibat) approved by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC)	0	7.95	19-03-2026
2	Nucala (mepolizumab) approved in China for use in adults with chronic obstructive pulmonary disease (COPD)	0	6.1	05-01-2026
3	Safety and Effects of Gildeuretinol Acetate on Retinal Atrophic Lesions in Stargardt Disease	0	3.79	03-09-2026
4	Nucala (mepolizumab) approved by the European Commission for the treatment of chronic obstructive pulmonary disease (COPD)	0	8.26	06-02-2026
5	Найден новый ранний признак болезни Альцгеймера	0	10	28-09-2026
6	New Guidance for Common Hair Loss Disorder	0	9.88	25-09-2026
7	Lipoprotein(a)-Lowering Medication Agent to Reduce Cardiovascular Events	0	12.34	25-09-2026
8	A new treatment has been approved for extensive-stage small cell lung cancer	0	7.66	24-09-2026
9	Vimseltinib approved in the UK for adults with tenosynovial giant cell tumours	0	5.27	14-08-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 7.44. Источник: www.news-medical.net.